Physician profile
David R Winters
NPI 1912984576
$7,303.54
in general payments reported to CMS, 2019-2025
45 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,068 · 2020: $1,388 · 2021: $726 · 2022: $128 · 2023: $825 · 2024: $790 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980 · Entertainment: $13.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.49 |
| Entertainment | $13.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,325.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $872.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $576.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $575.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $467.79 | 2019-2022 | |
| Astellas Pharma US INC | $407.67 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.24 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Novartis Pharmaceuticals Corporation | $282.59 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.00 | 2019-2025 | Jardiance |
| Abbott Laboratories | $224.56 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $196.16 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $165.48 | 2019-2021 | |
| Lilly USA, LLC | $155.82 | 2019-2025 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $134.70 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $121.31 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $103.24 | 2020-2021 | |
| Glaxosmithkline, LLC. | $86.87 | 2019-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $79.36 | 2019-2025 | Trintellix |
| Inspire Medical Systems, INC. | $68.07 | 2025 | Inspire |
| Optinose US, INC. | $67.98 | 2024-2025 | |
| Genentech USA, INC. | $65.12 | 2019-2020 | |
| Esperion Therapeutics, INC. | $45.59 | 2020-2021 | |
| Dexcom, INC. | $43.98 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $42.96 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $41.97 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $30.10 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.00 | 2025 | Caplyta |
| Eisai INC. | $28.15 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $28.07 | 2020 | |
| Medtronic, INC. | $22.38 | 2024 | Kyphon Express II Kyphopak Tray |
| Lundbeck LLC | $21.53 | 2024 | Rexulti |
| Insulet Corporation | $19.82 | 2024 | Omnipod |
| Upsher-Smith Laboratories LLC | $18.94 | 2021 | |
| Boston Scientific Corporation | $18.49 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.69 | 2023 | Nuzyra |
| Baxter Healthcare | $16.85 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Mylan Specialty L.P. | $16.75 | 2019 | |
| Viatris Specialty LLC | $15.15 | 2025 | Yupelri |
| Saluda Medical Americas, INC. | $14.69 | 2025 | Evoke |
| Exact Sciences Corporation | $13.72 | 2023 | Cologuard Collection Kit |
| Optos, INC. | $13.62 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Arbor Pharmaceuticals, INC. | $12.95 | 2019 | |
| Allergan, INC. | $12.65 | 2020 | |
| Celgene Corporation | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.